Liver Transplantation in Alcohol-related ...
Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
Title :
Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis.
Author(s) :
Ntandja Wandji, Line-Carolle [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Ningarhari, Massih [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Lassailly, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Dharancy, Sebastien [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Boleslawski, Emmanuel [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Mathurin, Philippe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Ningarhari, Massih [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Lassailly, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Dharancy, Sebastien [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Boleslawski, Emmanuel [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Mathurin, Philippe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Journal title :
Journal of Clinical and Experimental Hepatology
Pages :
127-138
Publication date :
2023-01-18
ISSN :
0973-6883
English keyword(s) :
alcohol
alcohol-related liver disease
alcohol-related hepatitis
liver transplantation
survival
alcohol-related liver disease
alcohol-related hepatitis
liver transplantation
survival
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications ...
Show more >Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications for liver transplantation (LT) worldwide especially after the arrival of direct-acting antivirals for chronic hepatitis C infection. Despite the risk of alcohol relapse, the outcomes of LT for ARLD are as good as for other indications such as hepatocellular carcinoma (HCC), with 1-, 5-, and 10- year survival rates of 85%, 74%, and 59%, respectively. Despite these good results, certain questions concerning LT for ARLD remain unanswered, in particular because of persistent organ shortages. As a result, too many transplantation centers continue to require 6 months of abstinence from alcohol for patients with ARLD before LT to reduce the risk of alcohol relapse even though compelling data show the poor prognostic value of this criterion. A recent pilot study even observed a lower alcohol relapse rate in patients receiving LT after less than 6 months of abstinence as long as addictological follow-up is reinforced. Thus, the question should not be whether LT should be offered to patients with ARLD but how to select patients who will benefit from this treatment.Show less >
Show more >Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications for liver transplantation (LT) worldwide especially after the arrival of direct-acting antivirals for chronic hepatitis C infection. Despite the risk of alcohol relapse, the outcomes of LT for ARLD are as good as for other indications such as hepatocellular carcinoma (HCC), with 1-, 5-, and 10- year survival rates of 85%, 74%, and 59%, respectively. Despite these good results, certain questions concerning LT for ARLD remain unanswered, in particular because of persistent organ shortages. As a result, too many transplantation centers continue to require 6 months of abstinence from alcohol for patients with ARLD before LT to reduce the risk of alcohol relapse even though compelling data show the poor prognostic value of this criterion. A recent pilot study even observed a lower alcohol relapse rate in patients receiving LT after less than 6 months of abstinence as long as addictological follow-up is reinforced. Thus, the question should not be whether LT should be offered to patients with ARLD but how to select patients who will benefit from this treatment.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Source :